Receptors, Opioid, kappa

"Receptors, Opioid, kappa" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

A class of opioid receptors recognized by its pharmacological profile. Kappa opioid receptors bind dynorphins with a higher affinity than endorphins which are themselves preferred to enkephalins.

Descriptor ID	D017473
MeSH Number(s)	D12.776.543.750.695.620.400 D12.776.543.750.720.600.610.400 D12.776.543.750.750.555.610.400
Concept/Terms	Receptors, Opioid, kappa Receptors, Opioid, kappa Opioid Receptors, kappa kappa Opioid Receptors Receptors, kappa Opioid Receptors, kappa kappa Receptor Receptor, kappa kappa Receptors kappa Opioid Receptor Opioid Receptor, kappa Receptor, kappa Opioid

Below are MeSH descriptors whose meaning is more general than "Receptors, Opioid, kappa".

Chemicals and Drugs [D]
Amino Acids, Peptides, and Proteins [D12]
Proteins [D12.776]
Membrane Proteins [D12.776.543]
Receptors, Cell Surface [D12.776.543.750]
Receptors, G-Protein-Coupled [D12.776.543.750.695]
Receptors, Opioid [D12.776.543.750.695.620]
Receptors, Opioid, kappa [D12.776.543.750.695.620.400]
Receptors, Neurotransmitter [D12.776.543.750.720]
Receptors, Neuropeptide [D12.776.543.750.720.600]
Receptors, Opioid [D12.776.543.750.720.600.610]
Receptors, Opioid, kappa [D12.776.543.750.720.600.610.400]
Receptors, Peptide [D12.776.543.750.750]
Receptors, Neuropeptide [D12.776.543.750.750.555]
Receptors, Opioid [D12.776.543.750.750.555.610]
Receptors, Opioid, kappa [D12.776.543.750.750.555.610.400]

Below are MeSH descriptors whose meaning is related to "Receptors, Opioid, kappa".

Below are MeSH descriptors whose meaning is more specific than "Receptors, Opioid, kappa".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Receptors, Opioid, kappa" by people in this website by year, and whether "Receptors, Opioid, kappa" was a major or minor topic of these publications.

Bar chart showing 15 publications over 11 distinct years, with a maximum of 3 publications in 2008

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1999	1	0	1
2000	1	0	1
2004	0	1	1
2007	0	1	1
2008	2	1	3
2009	2	0	2
2015	1	0	1
2017	1	0	1
2020	0	1	1
2021	1	0	1
2022	2	0	2

Below are the most recent publications written about "Receptors, Opioid, kappa" by people in Profiles.

Lee SJ, Logsdon AF, Yagi M, Baskin BM, Peskind ER, Raskind MM, Cook DG, Schindler AG. The dynorphin/kappa opioid receptor mediates adverse immunological and behavioral outcomes induced by repetitive blast trauma. J Neuroinflammation. 2022 Dec 03; 19(1):288.

View in: PubMed
Kopruszinski CM, Vizin R, Watanabe M, Martinez AL, de Souza LHM, Dodick DW, Porreca F, Navratilova E. Exploring the neurobiology of the premonitory phase of migraine preclinically - a role for hypothalamic kappa opioid receptors? J Headache Pain. 2022 Sep 30; 23(1):126.

View in: PubMed
Viscusi ER, Torjman MC, Munera CL, Stauffer JW, Setnik BS, Bagal SN. Effect of difelikefalin, a selective kappa opioid receptor agonist, on respiratory depression: A randomized, double-blind, placebo-controlled trial. Clin Transl Sci. 2021 09; 14(5):1886-1893.

View in: PubMed
Kopruszinski CM, Navratilova E, Swiokla J, Dodick DW, Chessell IP, Porreca F. A novel, injury-free rodent model of vulnerability for assessment of acute and preventive therapies reveals temporal contributions of CGRP-receptor activation in migraine-like pain. Cephalalgia. 2021 03; 41(3):305-317.

View in: PubMed
Xie JY, De Felice M, Kopruszinski CM, Eyde N, LaVigne J, Remeniuk B, Hernandez P, Yue X, Goshima N, Ossipov M, King T, Streicher JM, Navratilova E, Dodick D, Rosen H, Roberts E, Porreca F. Kappa opioid receptor antagonists: A possible new class of therapeutics for migraine prevention. Cephalalgia. 2017 Jul; 37(8):780-794.

View in: PubMed
Ng CM, Dombrowsky E, Lin H, Erlich ME, Moody DE, Barrett JS, Kraft WK. Population Pharmacokinetic Model of Sublingual Buprenorphine in Neonatal Abstinence Syndrome. Pharmacotherapy. 2015 Jul; 35(7):670-80.

View in: PubMed
Wang Y, Xu W, Huang P, Chavkin C, Van Bockstaele EJ, Liu-Chen LY. Effects of acute agonist treatment on subcellular distribution of kappa opioid receptor in rat spinal cord. J Neurosci Res. 2009 May 15; 87(7):1695-702.

View in: PubMed
Reyes BA, Chavkin C, van Bockstaele EJ. Subcellular targeting of kappa-opioid receptors in the rat nucleus locus coeruleus. J Comp Neurol. 2009 Jan 20; 512(3):419-31.

View in: PubMed
McLennan GP, Kiss A, Miyatake M, Belcheva MM, Chambers KT, Pozek JJ, Mohabbat Y, Moyer RA, Bohn LM, Coscia CJ. Kappa opioids promote the proliferation of astrocytes via Gbetagamma and beta-arrestin 2-dependent MAPK-mediated pathways. J Neurochem. 2008 Dec; 107(6):1753-65.

View in: PubMed
Wang Y, Van Bockstaele EJ, Liu-Chen LY. In vivo trafficking of endogenous opioid receptors. Life Sci. 2008 Nov 21; 83(21-22):693-9.

View in: PubMed

People

Explore

Similar Concepts

Top Journals

The Thomas Jefferson University web site, its contents and programs, is provided for informational and educational purposes only and is not intended as medical advice nor is it intended to create any physician-patient relationship. Please remember that this information should not substitute for a visit or a consultation with a health care provider. The views or opinions expressed in the resources provided do not necessarily reflect those of Thomas Jefferson University, Thomas Jefferson University Hospital, or the Jefferson Health System or staff.
Please read our Privacy Statement